Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Background: Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant PC (CRPC). We investigated a mouse model of PC as well as specimens from PC patients to unravel an unsuspected contribution of thymus-derived T lymphocytes and the intestinal microbiota in the efficacy of ADT. Methods: Preclinical experiments were performed in PC-bearing mice, immunocompetent or immunodeficient. In parallel, we prospectively included 65 HSPC and CRPC patients (Oncobiotic trial) to analyze their feces and blood specimens. Results: In PC-bearing mice, ADT increased thymic cellularity and output. PC implanted in T lymphocyte-depleted or athymic mice responded less efficiently to ADT than in immunocompetent mice. Moreover, depletion of the intestinal microbiota by oral antibiotics reduced the efficacy of ADT. PC reduced the relative abundance of Akkermansia muciniphila in the gut, and this effect was reversed by ADT. Moreover, cohousing of PC-bearing mice with tumor-free mice or oral gavage with Akkermansia improved the efficacy of ADT. This appears to be applicable to PC patients because long-term ADT resulted in an increase of thymic output, as demonstrated by an increase in circulating recent thymic emigrant cells (sjTRECs). Moreover, as compared with HSPC controls, CRPC patients demonstrated a shift in their intestinal microbiota that significantly correlated with sjTRECs. While feces from healthy volunteers restored ADT efficacy, feces from PC patients failed to do so. Conclusions: These findings suggest the potential clinical utility of reversing intestinal dysbiosis and repairing acquired immune defects in PC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“polychemotherapy and endocrine therapy (such as androgen deprivation) can modulate the alpha and beta diversities of the microbiota, which have been proposed to affect treatment-related adverse events27,28 as well as drug metabolism and efficacy29,30.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Together, these findings validate those obtained in preclinical avatar models involving the oral transfer of patient-derived stool samples to mice harbouring hepatocarcinomas103, sarcomas, or kidney, lung or prostate tumours28,41.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationInduction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“21 22 23 This applies as well to estrogen receptor antagonists, which are used for the treatment of hormone receptor-positive breast cancer.”
Self-citationCommensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204
NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis
Elinav, E., Strowig, T., Kau, A. L., Henao-Mejia, J., Thaiss, C. A., Booth, C. J., Peaper, D. R., Bertin, J., Eisenbarth, S. C., Gordon, J. I., et al. (2011) · Cell · doi:10.1016/j.cell.2011.04.022 · Cited by 2,024
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Self-citationImmunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Self-citationThe microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
Self-citationMutations in T-cell antigen receptor genes α and β block thymocyte development at different stages
Mombaerts, P., Clarke, A. R., Rudnicki, M. A., Iacomini, J., Itohara, S., Lafaille, J. J., Wang, L., Ichikawa, Y., Jaenisch, R., Hooper, M. L., et al. (1992) · Nature · doi:10.1038/360225a0 · Cited by 1,112
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952 · cited 1×
“19 20 Such agents induce immunogenic cell death, rendering malignant cells recognizable to the immune system.”
Self-citationDaillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897
Self-citationThe microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777 · cited 1×
“Indeed, recent work by multiple groups has revealed the cardinal importance of the gut microbiota in determining the general immune tonus, 34–36 as well as cross-reactive cancer antigen-specific immune responses.”
Self-citationRoseburia Spp.: A Marker of Health?
Tamanai-Shacoori, Z., Smida, I., Bousarghin, L., Loreal, O., Meuric, V., Fong, S. B., Bonnaure-Mallet, M., & Jolivet-Gougeon, A. (2017) · Future Microbiology · doi:10.2217/fmb-2016-0130 · Cited by 746
Mittelbrunn, M., & Kroemer, G. (2021) · Nature Immunology · doi:10.1038/s41590-021-00927-z · Cited by 702 · cited 1×
“33 Hence, it is conceivable that ADT has local as well as systemic effects on antitumor immune responses.”
Self-citationCascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01224-2 · Cited by 618
Yoon, H. S., Cho, C. H., Yun, M. S., Jang, S. J., You, H. J., Kim, J.-H., Han, D., Cha, K. H., Moon, S. H., Lee, K., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00880-5 · Cited by 602
The gut microbiota influences anticancer immunosurveillance and general health
Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523 · cited 2×
“In accord with this speculation, CRPC patients that had undergone prolonged ADT manifested an increase in recent thymic emigrants positive for sjTREC.”
Self-citationLópez-Otín, C., & Kroemer, G. (2021) · Cell · doi:10.1016/j.cell.2020.11.034 · Cited by 499
Self-citationObeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474
Self-citationA New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays
Marangoni, E., Vincent-Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Cremoux, P., de Plater, L., Guyader, C., De Pinieux, G., Judde, J.-G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0078 · Cited by 422
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406
Self-citationCross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396
Self-citationT cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
Mercader, M., Bodner, B. K., Moser, M. T., Kwon, P. S., Park, E. S. Y., Manecke, R. G., Ellis, T. M., Wojcik, E. M., Yang, D., Flanigan, R. C., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251140998 · Cited by 393
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Bezu, L., Gomes-de-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 390
Self-citationCommensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Pernigoni, N., Zagato, E., Calcinotto, A., Troiani, M., Mestre, R. P., Calì, B., Attanasio, G., Troisi, J., Minini, M., Mosole, S., et al. (2021) · Science · doi:10.1126/science.abf8403 · Cited by 323
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302
Self-citationAndrogen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
Drake, C. G., Doody, A. D. H., Mihalyo, M. A., Huang, C.-T., Kelleher, E., Ravi, S., Hipkiss, E. L., Flies, D. B., Kennedy, E. P., Long, M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.027 · Cited by 289 · cited 1×
“24 Both in preclinical models and in PC patients, ADT causes an increase of the immune infiltrate of the malignant tumor and the adjacent normal prostate 25–29 suggesting that ADT triggers at least a transient immune response, likely against both normal and cancer-specific antigens.”
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Self-citationPage, S. T., Plymate, S. R., Bremner, W. J., Matsumoto, A. M., Hess, D. L., Lin, D. W., Amory, J. K., Nelson, P. S., & Wu, J. D. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00484.2005 · Cited by 170
Grajeda-Iglesias, C., Durand, S., Daillère, R., Iribarren, K., Lemaitre, F., Derosa, L., Aprahamian, F., Bossut, N., Nirmalathasan, N., Madeo, F., et al. (2021) · Aging · doi:10.18632/aging.202739 · Cited by 161
Self-citationWatson, P. A., Ellwood-Yen, K., King, J. C., Wongvipat, J., LeBeau, M. M., & Sawyers, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3441 · Cited by 159
Resistance to second-generation androgen receptor antagonists in prostate cancer
Schmidt, K. T., Huitema, A. D. R., Chau, C. H., & Figg, W. D. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00438-4 · Cited by 153
Sfanos, K. S., Markowski, M. C., Peiffer, L. B., Ernst, S. E., White, J. R., Pienta, K. J., Antonarakis, E. S., & Ross, A. E. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0061-x · Cited by 147
Androgen deprivation and immunotherapy for the treatment of prostate cancer
Gamat, M., & McNeel, D. G. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0145 · Cited by 145
Self-citationImmunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Self-citationImmunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17644-0 · Cited by 138
Self-citationDaisley, B. A., Chanyi, R. M., Abdur-Rashid, K., Al, K. F., Gibbons, S., Chmiel, J. A., Wilcox, H., Reid, G., Anderson, A., Dewar, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18649-5 · Cited by 128
Davidsson, S., Ohlson, A., Andersson, S., Fall, K., Meisner, A., Fiorentino, M., Andrén, O., & Rider, J. R. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.164 · Cited by 125
Ness, N., Andersen, S., Valkov, A., Nordby, Y., Donnem, T., Al-Saad, S., Busund, L.-T., Bremnes, R. M., & Richardsen, E. (2014) · The Prostate · doi:10.1002/pros.22862 · Cited by 114
Yonekura, S., Terrisse, S., Alves Costa Silva, C., Lafarge, A., Iebba, V., Ferrere, G., Goubet, A.-G., Fahrner, J.-E., Lahmar, I., Ueda, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0999 · Cited by 112
Self-citationBeneficial autoimmunity improves cancer prognosis
Zitvogel, L., Perreault, C., Finn, O. J., & Kroemer, G. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00508-x · Cited by 112 · cited 1×
“30 Of note, testosterone is one of the best known endogenous accelerators of thymic atrophy, 31 32 suggesting that ADT might reverse thymic aging, which is one of the drivers of T cell aging and the senescence-associated decline in anticancer immunosurveillance.”
Self-citationImmune Checkpoint Inhibitors in Prostate Cancer
Venkatachalam, S., McFarland, T. R., Agarwal, N., & Swami, U. (2021) · Cancers · doi:10.3390/cancers13092187 · Cited by 106
Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress
Humeau, J., Sauvat, A., Cerrato, G., Xie, W., Loos, F., Iannantuoni, F., Bezu, L., Lévesque, S., Paillet, J., Pol, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911622 · Cited by 95
Self-citationYang, Y., Attwood, K., Bshara, W., Mohler, J. L., Guru, K., Xu, B., Kalinski, P., & Chatta, G. (2021) · The Prostate · doi:10.1002/pros.24068 · Cited by 88
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer
Flammiger, A., Bayer, F., Cirugeda‐Kühnert, A., Huland, H., Tennstedt, P., Simon, R., Minner, S. J. P., Bokemeyer, C., Sauter, G., Schlomm, T., et al. (2012) · Apmis · doi:10.1111/j.1600-0463.2012.02924.x · Cited by 87
Sorrentino, C., Musiani, P., Pompa, P., Cipollone, G., & Di Carlo, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2804 · Cited by 84 · cited 1×
“24 Both in preclinical models and in PC patients, ADT causes an increase of the immune infiltrate of the malignant tumor and the adjacent normal prostate 25–29 suggesting that ADT triggers at least a transient immune response, likely against both normal and cancer-specific antigens.”
Wu, Q., Tian, A.-L., Li, B., Leduc, M., Forveille, S., Hamley, P., Galloway, W., Xie, W., Liu, P., Zhao, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002722 · Cited by 83
Self-citationCan we harness the microbiota to enhance the efficacy of cancer immunotherapy?
Finlay, B. B., Goldszmid, R., Honda, K., Trinchieri, G., Wargo, J., & Zitvogel, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0374-6 · Cited by 81
Self-citationPEARCE, P., KHALID, B. A. K., & FUNDER, J. W. (1981) · Endocrinology · doi:10.1210/endo-109-4-1073 · Cited by 74 · cited 1×
“30 Of note, testosterone is one of the best known endogenous accelerators of thymic atrophy, 31 32 suggesting that ADT might reverse thymic aging, which is one of the drivers of T cell aging and the senescence-associated decline in anticancer immunosurveillance.”
Depommier, C., Vitale, R. M., Iannotti, F. A., Silvestri, C., Flamand, N., Druart, C., Everard, A., Pelicaen, R., Maiter, D., Thissen, J.-P., et al. (2021) · Cells · doi:10.3390/cells10010185 · Cited by 73
Nardone, V., Botta, C., Caraglia, M., Martino, E. C., Ambrosio, M. R., Carfagno, T., Tini, P., Semeraro, L., Misso, G., Grimaldi, A., et al. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1235666 · Cited by 72
Treatment and trials in non-metastatic castration-resistant prostate cancer
Lokeshwar, S. D., Klaassen, Z. W. A., & Saad, F. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00470-4 · Cited by 65
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
Baruch, E. N., Wang, J., & Wargo, J. A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0877 · Cited by 58 · cited 1×
“Indeed, recent work by multiple groups has revealed the cardinal importance of the gut microbiota in determining the general immune tonus, 34–36 as well as cross-reactive cancer antigen-specific immune responses.”
A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency
Naour, J. L., Liu, P., Zhao, L., Adjemian, S., Sztupinszki, Z. M., Taïeb, J., Mulot, C., Silvin, A., Dutertre, C., Ginhoux, F., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0465 · Cited by 56
Self-citationGender‐Related Differences in the Rates of Age AssociatedThymic Atrophy
Aspinall, R., & Andrew, D. (2001) · Journal of Immunology Research · doi:10.1155/2001/17064 · Cited by 42
Li, K.-M., Wang, L., Wong, C. Y., Chiu, P. K., Teoh, J. Y., Kwok, H. S., Leung, S. C. H., Wong, S. H., Tsui, S. K., & Ng, C. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00360-1 · Cited by 36
Shabat, Y., Lichtenstein, Y., & Ilan, Y. (2020) · Inflammation · doi:10.1007/s10753-020-01348-0 · Cited by 34
Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype
Tong, D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103370 · Cited by 32
Immunosurveillance against cancer-associated hyperploidy
Senovilla, L., Galluzzi, L., Mariño, G., Vitale, I., Castedo, M., & Kroemer, G. (2012) · Oncotarget · doi:10.18632/oncotarget.753 · Cited by 12
Self-citationDiagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol
Beyer, K., Moris, L., Lardas, M., Haire, A., Barletta, F. M., Scuderi, S., Vradi, E., Gandaglia, G., Omar, M. I., MacLennan, S., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-040531 · Cited by 4
Thymus in Experimental Carcinogenesis of the Prostate Gland
Borodin, Y. I., Lomshakov, A. A., Astashov, V. V., Васильевич, К. О., Mayorov, A. P., & Ларионов, П. М. (2014) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-014-2652-4 · Cited by 1
Cited by
Bacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
“Overall, these studies highlight the importance of DPP4Is on gut microbiota and reveal promising strategies to improve glucose homeostasis and IVDR.”
BackgroundInfluentialGut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
Recent findings in Akkermansia muciniphila-regulated metabolism and its role in intestinal diseases
Liu, M.-J., Yang, J.-Y., Yan, Z.-H., Hu, S., Li, J.-Q., Xu, Z.-X., & Jian, Y.-P. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.08.029 · Cited by 166
Metadata
- Authors
- Terrisse, S., Goubet, A.-G., Ueda, K., Thomas, A. M., Quiniou, V., Thelemaque, C., Dunsmore, G., Clave, E., Gamat-Huber, M., Yonekura, S., Ferrere, G., Rauber, C., Pham, H. P., Fahrner, J.-E., Pizzato, E., Ly, P., Fidelle, M., Mazzenga, M., Costa Silva, C. A., Armanini, F., Pinto, F., Asnicar, F., Daillère, R., Derosa, L., Richard, C., Blanchard, P., Routy, B., Culine, S., Opolon, P., Silvin, A., Ginhoux, F., Toubert, A., Segata, N., McNeel, D. G., Fizazi, K., Kroemer, G., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- INSERM U1015, Gustave Roussy, Villejuif, France
- Kurume University (JP)
- University of Trento (IT)
- Toulouse White Biotechnology (FR)
- UW Carbone Cancer Center, Madison, Wisconsin, USA
- Institut Gustave Roussy (FR)
- Centre Hospitalier de l’Université de Montréal (CA)
- Université Paris Cité (FR)
- University of Wisconsin–Madison (US)
- Université Paris-Saclay (FR)
- Corresponding author
- Kroemer, Guido
- Zitvogel, Laurence
- ORCID
- Terrisse, Safae
- Thomas, Andrew Maltez
- Quiniou, Valentin
- Dunsmore, Garett
- Clave, Emmanuel
- Gamat-Huber, Melissa
- Yonekura, Satoru
- Ferrere, Gladys
- Rauber, Conrad
- Pham, Hang Phuong
- Fahrner, Jean-Eudes
- Ly, Pierre
- Fidelle, Marine
- Mazzenga, Marine
- Armanini, Federica
- Pinto, Federica
- Asnicar, Francesco
- Daillère, Romain
- Derosa, Lisa
- Richard, Corentin
- Blanchard, Pierre
- Routy, Bertrand
- Culine, Stéphane
- Opolon, Paule
- Silvin, Aymeric
- Ginhoux, Florent
- Toubert, Antoine
- Segata, Nicola
- McNeel, Douglas G
- Fizazi, Karim
- Kroemer, Guido
- Zitvogel, Laurence
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2022-03
- Volume
- 10
- Issue
- 3
- Pages
- e004191
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC8928383
- OpenAlex
- W4221060919
- Cited by
- 80
- References
- 65
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 18 · 2023: 14 · 2022: 8
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion, cc-by-nc)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- H2020 ONCOBIOME (N°825410)
- Germano-French ANR Ileobiome (19-CE15-0029-01)
- NIH (NCI P01 CA250927)
- AMMICa (US23/CNRS UMS3655)
- LabEx Immuno-Oncology (ANR-18-IDEX-0001)
- RHU Torino Lumière (ANR-16-RHUS-0008)
- French Government’s Investissement d’Avenir (ANR-10-LABX-69-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- prostate cancer, androgen deprivation therapy, castration-resistant prostate cancer, gut microbiota, Akkermansia muciniphila, thymic output, immunodeficiency, dysbiosis, oral antibiotics, tumor-bearing mice, fecal microbiota transplantation
- MeSH terms
- Gastrointestinal Microbiome, Androgen Antagonists, Androgens, Animals, Humans, Immune System, Male, Mice, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.